Zealand Pharma and Generate Biomedicines team up on AI-designed obesity therapies
What's the deal? On 13 October 2026, Generate Biomedicines and Zealand Pharma announced a multi-target collaboration and licence agreement to design and develop multispecific protein therapeutics — medicines engineered to act on more than one biological target at once — for obesity and other metabolic diseases. The work will use Generate's platform, which combines generative AI with high-throughput wet-lab experimentation to design proteins. Generate will receive USD 30 million up front, up to USD 35 million in early preclinical milestones, and nearly USD 1.2 billion in development, regulatory and commercial milestones, plus tiered royalties on two initial programmes, with an option to add a third.
How it will work: Generate leads research through the selection of lead drug candidates, while Zealand Pharma is responsible for clinical development, regulatory submissions and worldwide commercialisation. The deal broadens Zealand's toolkit beyond its traditional peptide-based medicines and extends Generate's platform into obesity and metabolic disease for the first time.
Why it matters: The agreement is the latest in a wave of obesity-focused partnerships as drugmakers search for successors to the blockbuster GLP-1 weight-loss drugs. Zealand already co-develops the obesity candidate petrelintide with Roche under a deal worth up to USD 5.3 billion agreed in 2025.
Read more: GlobeNewswire, 13 October 2026